Cannabis policy has changed faster over the past fifteen years than in the century before it. The global picture is no longer prohibition with a few exceptions — it is four distinct models operating simultaneously, often in neighbouring countries.
Policy moves quickly. This is an overview of the models in use, not legal advice. Cannabis laws change frequently and enforcement varies within countries. Verify the current position before travelling or making any commercial decision.
The Four Models
Full legalisation. Adult-use cannabis is legal, regulated and taxed, with a licensed commercial supply chain. Uruguay was first, in 2013. Canada followed nationally in 2018. In the United States, a majority of states have legalised adult use while federal prohibition remains in place — a contradiction with real consequences for banking, transport and enforcement.
Medical-only frameworks. Cannabis is available by prescription or recommendation through a regulated system, with recreational use still prohibited. This is now the most common model. Germany, Australia, Israel, the United Kingdom, and a substantial number of other countries operate versions of it, though access varies from genuinely accessible to nominal.
Decriminalisation. Possession of small amounts is not a criminal offence, but supply remains illegal. Portugal is the widely cited example, having decriminalised all drug possession in 2001 and redirected resources toward treatment. Decriminalisation addresses criminal justice consequences without creating a legal supply, which is a meaningful difference.
Prohibition. Still the position in much of Asia, the Middle East and Africa, in some cases with severe penalties.
How Medical Access Differs in Practice
“Medical cannabis is legal” describes very different realities depending on where you are.
Some programmes are broadly accessible — Oklahoma, for example, has no list of qualifying conditions, leaving the decision to the recommending physician. Others restrict eligibility to a narrow set of conditions, usually after conventional treatments have failed, with specialist approval required. A few permit cannabis-derived medicines only for a handful of licensed indications, which is closer to pharmaceutical regulation than to a cannabis programme.
The practical test is not whether a framework exists but how many patients actually receive product through it. On that measure, several countries with medical frameworks have very low real-world access.
What Legalisation Does to Testing Standards
This is where the models diverge most sharply, and it is the part with direct consequences for product quality.
Countries that regulate cannabis as a medicine generally apply existing pharmaceutical standards — Good Manufacturing Practice, pharmacopoeial monographs specifying methods and limits, and full batch documentation. This produces a rigorous, standardised regime, with correspondingly high production costs and slow routes to market. Several European medical programmes work this way.
Countries that regulate cannabis as its own category write bespoke rules. Canada does this federally, which gives it one consistent national standard. The United States does it state by state, which produces the patchwork described in how testing rules differ across states.
Decriminalised markets have no testing regime at all, because there is no legal supply chain to regulate. Consumers get the criminal-justice benefit without the product-safety benefit — which is a genuine limitation of the model, and the reason contamination risks in untested cannabis products persist there.
The International Treaty Layer
Cannabis is controlled under three United Nations conventions, principally the 1961 Single Convention on Narcotic Drugs. Countries legalising adult use are therefore in tension with treaty obligations, which is part of why several have taken slower or more constrained routes than domestic politics alone would explain.
The 2020 reclassification of cannabis under the 1961 Convention — removing it from the schedule reserved for substances with no recognised medical value — was a meaningful signal, though it did not change any country’s obligations regarding non-medical use.
What Legalisation Consistently Produces
Across markets that have legalised, several patterns recur reliably enough to be predictable.
An initial supply shortage, then oversupply. Almost every legalised market has followed this arc. Licensed production takes time to come online, then overshoots.
Price decline. Legal prices start above illicit prices, then fall — sometimes below them — as production scales. Oklahoma’s experience is a clear example, covered in Oklahoma’s cannabis market.
Consolidation. Early markets fragment across many small operators; capital requirements and compliance overheads then favour scale.
Tightening regulation. Initial frameworks are usually revised toward stricter testing, labelling and marketing rules once problems surface. Requirements very rarely loosen.
Persistent illicit supply. Legal markets do not eliminate illicit ones, particularly where taxes are high or licensed retail is thin. Which means untested product remains in circulation even in mature legal markets.
Why This Matters Beyond Policy Interest
For operators, the international picture is the clearest available preview of where domestic regulation is heading. Markets that legalised earlier have already worked through the problems newer markets are encountering, and their responses — mandatory accreditation, standardised methods, blind proficiency testing, tighter marketing rules — are the likely template.
Pharmaceutical-grade frameworks in particular show what cannabis testing looks like when it is held to the standard applied to medicines. Some of that is already arriving in US state programmes. More on the trajectory in the future of cannabis lab testing and the future of the cannabis industry.
For how the regulatory framework in the United States reached its current shape, see from the Marihuana Tax Act to OMMA.